Cancer Therapeutics

Cancer Therapeutics

Preclinical CRO Services for Immuno-Oncology

Discover the power of Anilocus’s in vivo preclinical CRO services for immuno-oncology therapies. As a growing CRO, we are committed to advancing the fight against cancer. With a deep understanding of the impact cancer has on millions of lives, our team conducts thorough in vivo safety and efficacy assessments for oncology therapeutics.

Whether you’re developing immunotherapies, small molecules, targeted antibodies, or outsourcing research for your laboratory studies in the progression of cancer, our preclinical CRO services offer the expertise and resources that you need. Join us in the battle against cancer and let our team support your research efforts. Take the first step today and contact us!

At AniLocus, we offer in vivo contract research services and a wide variety of orthotopic cancer models to pharmaceutical and medical device companies designing therapeutics for a range of disorders.

Contact us! Learn more about our in vivo services for immuno-oncology therapies:

We offer an array of specialized in vivo contract research services tailored to your specific needs. Our commitment to advancing science and delivering quality results ensures that your immuno-oncology therapies receive the comprehensive evaluation they deserve.

Our Immuno-Oncology Research Services Safety & Efficacy Assessments for Multiple Therapeutics:

  • Adoptive Cell Therapies (ACT): Harness the potential of adoptive cell therapies with our expert guidance and precise assessments.
  • Chimeric Antigen Receptor (CAR) T-Cell Therapy: Explore the cutting-edge field of CAR T-cell therapy with our support in safety and efficacy evaluations.
  • Alkylating Agents: Investigate the safety and efficacy of alkylating agents in the context of immuno-oncology research.
  • Antimetabolites: Assess the impact of antimetabolites on the immune response and tumor microenvironment.
  • Histone Deacetylase Inhibitors: Explore the potential of histone deacetylase inhibitors in enhancing the efficacy of immunotherapies.
  • Hormonal Agents: Investigate the interactions between hormonal agents and the immune system in the context of cancer treatment.
  • Monoclonal Antibodies: Assess the safety and efficacy of monoclonal antibodies targeting cancer-specific antigens.
  • Protein Kinase Inhibitors: Explore the role of protein kinase inhibitors in modulating immune responses against cancer.
  • Taxanes: Evaluate the compatibility of taxanes with immuno-oncology therapies.
  • Topoisomerase Inhibitors: Investigate the potential synergy between topoisomerase inhibitors and immunotherapeutic approaches.
  • Vinca Alkaloids: Assess the safety and efficacy of vinca alkaloids in immuno-oncology contexts.
  • Other Antineoplastic Agents: Explore a wide range of antineoplastic agents in the context of immunotherapy and their potential synergistic effects.

At AniLocus, we understand the intricate nature of immuno-oncology research. Our team of dedicated experts is committed to providing you with precise and reliable in vivo assessments, ensuring that your therapies reach their full potential. Collaborate with us to unlock new possibilities in the realm of immuno-oncology and bring innovative treatments to the forefront of cancer care.

Cancer Animal Models for Immuno-Oncology Research​

Rodent models are essential tools in immuno-oncology research, allowing scientists to study various aspects of the immune system’s role in cancer development, progression, and treatment.

Here’s a comprehensive list of rodent models we can offer for immuno-oncology research. You can request any model for studies with our team:

Syngeneic Mouse Models:

  • Murine cancer cell lines are implanted in immunocompetent mice from the same strain.
  • Examples: B16 melanoma, CT26 colon carcinoma, 4T1 breast cancer.

Xenograft Models:

  • Human cancer cell lines or patient-derived tumor cells are implanted into immunodeficient mice.
  • Allows the study of human-specific immune responses and therapies.
  • Examples: NOD/SCID/IL2rγnull (NSG) mice, NOD/Shi-scid IL2rγnull (NOG) mice

Genetically Engineered Mouse Models (GEMMs):

  • Mice are genetically modified to develop spontaneous tumors that mimic human cancers.
  • Allows for the study of tumor initiation, progression, and immune interactions.
  • Examples: KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC)

Patient-Derived Xenograft (PDX) Models:

  • Patient tumor tissues are implanted into immunodeficient mice.
  • Retains the tumor’s genetic and histological characteristics.
  • Ideal for personalized medicine and immune checkpoint inhibitor testing.

Humanized Mouse Models:

  • Mice are engrafted with human immune cells, such as T cells, B cells, and hematopoietic stem cells.
  • Allows the study of human immune responses in the context of cancer.
  • Examples: NSG mice with human immune cell engraftment.

Orthotopic Models:

  • Tumor cells are implanted into the organ or tissue of interest.
  • Mimics the tumor microenvironment and allows the study of organ-specific immune responses.
  • Examples: Orthotopic breast cancer models, orthotopic lung cancer models.

Spontaneous Transgenic Models:

  • Mice carry specific oncogenes or gene mutations that predispose them to develop tumors.
  • Allows the study of immune responses in a context that mimics human oncogenesis.
  • Examples: Lck-MyrAkt transgenic mice for lymphoma studies.

Transplantable Allograft Models:

  • Tumor tissues or cells from one mouse strain are implanted into another, causing an immune response.
  • Useful for studying tumor rejection and graft-versus-host reactions.

Chemically Induced Tumor Models:

  • Tumors are induced in mice through the administration of carcinogenic chemicals or agents.
  • Useful for investigating the immune response to chemically induced tumors.

Cross-Breeding Models:

  • Different mouse strains are crossbred to study how genetic variations influence tumor development and immune responses.
  • Allows for the identification of candidate genes involved in immune modulation.

Inducible Models:

  • Mice carry inducible genetic constructs that allow researchers to control the timing and location of tumor development.
  • Useful for studying immune responses at different stages of tumor progression.

Immunocompromised Models:

  • Mice with specific immune system deficiencies are used to study how different immune components impact tumor development and response to therapies.
  • Examples: SCID (Severe Combined Immunodeficiency) mice, Rag1/Rag2 knockout mice.

Immune Checkpoint Blockade Models:

  • Mice are used to evaluate the effectiveness of immune checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies.
  • Valuable for assessing immunotherapeutic approaches.

Microbiota-Altered Models:

  • Mice with specific gut microbiota compositions are used to investigate the influence of the microbiome on immune responses to cancer.

Conditional Knockout Models:

  •  Mice with conditional knockout of specific genes involved in immune regulation are used to study the impact of these genes on tumor development and immune response.

These rodent models offer a wide range of options for investigating the complex interactions between the immune system and cancer, ultimately contributing to the development of novel immunotherapies and treatments for cancer patients.

Frequently Asked Questions About Immuno-Oncology CRO Services

Sponsors often ask the following questions about immuno-oncology CRO services at Anilocus: 

Immuno-oncology research focuses on harnessing the body’s immune system to fight cancer. It is vital for drug development because it has led to groundbreaking therapies like immune checkpoint inhibitors, which have shown remarkable efficacy in treating various cancers. Understanding the immune response in cancer allows us to develop more targeted and effective treatments with fewer side effects.

Preclinical studies in immuno-oncology include assessing the safety and efficacy of immunotherapies, studying immune system interactions with tumors, and evaluating combination therapies. Key studies involve adoptive cell therapies, tumor microenvironment analysis, and in vivo assessments of candidate drugs.

Outsourcing offers several benefits, including access to specialized expertise, state-of-the-art facilities, and cost-effective solutions. It allows your team to focus on core research while leveraging the capabilities of our CRO to conduct rigorous preclinical studies efficiently and in parallel with your team. This expedites studies and makes timelines more manageable for your team.

Ethical treatment of animals is paramount. Choose a CRO with a strong commitment to animal welfare, adherence to regulatory guidelines (e.g., IACUC approvals), and a focus on minimizing animal discomfort through humane practices and anesthesia.

Preclinical study timelines vary based on the complexity of the research. Generally, it can take several months to a year or more, encompassing study design, conduct, data analysis, and reporting. The timeline is influenced by the specific goals and scope of the study.

Effective collaboration begins with clear communication of your research goals, timelines, and expectations. Maintain open lines of communication, provide regular feedback, and work closely with the CRO’s scientific team to ensure alignment with your research objectives. A collaborative approach ensures successful preclinical studies for cancer drug development.

Contact us to learn more about our services.